Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 20/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680037 | 0.79 | PDE3A (0.39) | PDE3APDE3BPDE4B | |
| SCHEMBL5183107 | 0.77 | PDE3A (0.44) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL16150403 | 0.76 | PDE3A (0.55) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7380645 | 0.68 | PDE3A (0.54) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL16150009 | 0.66 | PDE3A (0.55) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL2847376 | 0.66 | PDE3A (0.55) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL2810853 | 0.65 | MAPT (0.43) | — | |
| SCHEMBL6563643 | 0.65 | PDE3A (0.42) | PDE3APDE3BPDE4B | |
| SCHEMBL2847471 | 0.65 | PDE3A (0.44) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL184199 | 0.64 | PDE3A (0.43) | PDE3APDE3BPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472229-A1 | 5-RING HETEROCYCLES USED AS ANTIVIRAL AGENTS | Bayer HealthCare AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003064394-A1 | 5-RING HETEROCYCLES USED AS ANTIVIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2003-08-07 | — | — | WO | disclosed |